-
Rare pediatric epilepsy new drug! Fintepla (Finteplamin) Treatment of Dravet Syndrome Phase 3 Phase
Time of Update: 2020-09-26
results showed that the study achieved the main goal: patients in the Fintepla 0.7mg/kg/day group had an average monthly reduction in convulsive seizures by 64.8% compared to the placebo group.
-
The first plant-derived cannabinoid new anti-epileptic drug! FDA approves Epidiolex: Treatment of nodule sclerosis (TSC)-related epilepsy.
Time of Update: 2020-08-06
in the United States and the European Union, Epidyolex/Epidiolex has been granted the right to treat DS, LGS, TSC-related seizures, each of which is a rare, severe, childhood-related type of drug refractive epilepsy.
-
Rare new drug for childhood epilepsy! FDA approves Fintepla (fenfluramin oral solution) for the treatment of Dravet syndrome!
Time of Update: 2020-07-19
, June 25, 2020 / PRNewswire/ -- Zogenix is a pharmaceutical company dedicated to the development of treatments for rare diseases Recently, the company announced that the U.S Food and Drug Administ
-
Delisted "old drug" gets new FDA approval for breakthrough therapy to treat rare childhood epilepsy
Time of Update: 2020-07-19
Dravet syndrome is a rare childhood seizure characterized by frequent and severe refractive seizures, associated hospitalizations and medical emergencies, significant developmental and motor disorders
-
Delisted "old drug" gets new FDA approval for breakthrough therapy to treat rare childhood epilepsy
Time of Update: 2020-07-18
26, Zogenix announced that the U.S FDA has approved the listing of an oral solution for Fintepla (fenfluramine, fenfluramine) to treat seizures associated with Dravet syndrome in patients 2 years and
-
New epilepsy drugs! The new fine-particle preparation sinnuse of Fycompa (Weiketai ®, LulenPanai
Time of Update: 2020-07-17
July 12, 2020 // Eisai recently announced the launch of the anti-epileptic drug Fycompa (Weketai®, generic name: perampanel, perlumpanay, 1%, 100 grams per bottle) new fine particle preparations appr
-
New epilepsy drug dp-vpa jointly developed by Enhua pharmaceutical and d-pharm in Israel has entered the phase III clinical trial
Time of Update: 2020-04-03
Jiangsu Enhua Pharmaceutical Co., Ltd said in the morning of February 14 that the dp-vpa innovative drug jointly developed by Enhua pharmaceutical and Israeli d-pharm company is currently in the phase
-
The first new anti epileptic drug from cannabinoids! Epidiolex applied for new indications
Time of Update: 2020-02-24
February 24, 2020 / BIOON / -- GW Pharma, a British pharmaceutical company, is a global leader in the field of cannabinoid prescription medicine science, development and commercialization Recently, th
-
A rare new drug for epilepsy in children! Fintepla (fenfluramine oral liquid) has been successfully
Time of Update: 2020-02-11
February 11, 2020 / BIOON / -- zogenix is a pharmaceutical company dedicated to the development of rare disease treatment drugs Recently, the company published the positive top line results of the glo
-
New drugs for epilepsy! The paediatric indications and fine particle preparation of Weicai fycompa
Time of Update: 2020-01-24
January 24, 2020 / BIOON/ --Eisai recently announced that the application for supplementary new drugs (SNDA) of the antiepileptic drug fycompa has been approved by the Ministry of health, labor and we
-
The first new anti epileptic drug from cannabinoids! Epidiolex is a successful treatment for stage III epilepsy related to tuberous sclerosis (TSC)!
Time of Update: 2019-12-31
December 31, 2019 / BIOON / -- GW Pharma, a British pharmaceutical company, is a global leader in the research and development of plant-based cannabinoid treatment products It is committed to the disc
-
New drugs for epilepsy! South Korea SK biopharmaceutical xcopri (cenobamate) has been approved
Time of Update: 2019-11-25
November 25, 2019 / BIOON / -- SK biopharmaceuticals of South Korea and its US subsidiary SK Life Sciences recently jointly announced that the US Food and Drug Administration (FDA) has approved the xc
-
New drug express! The gospel of 50 million epilepsy patients
Time of Update: 2019-11-24
Cenobamate (trade name: XCOPRI?), developed by SK Life Science (a subsidiary of SK Biopharmaceuticals), is used to treat partial-onset seizures (POS) and approved by the FDA on 21 November 2019 Figure
-
Good news for epileptics in China! The new generation antiepileptic drug fycompa of Weicai has been approved by China for epilepsy patients aged ≥ 12 years!
Time of Update: 2019-10-17
October 17, 2019 / BIOON / - Japanese pharmaceutical company Eisai recently announced that the National Drug Administration of China (nmpa) has approved the new generation of antiepileptic drug fycomp
-
Great news for intractable pediatric epilepsy! Epidiolex, the first new anti epileptic drug
Time of Update: 2018-11-02
November 2, 2018 / BIOON / -- GW Pharma, a British pharmaceutical company, is a global leader in the research and development of plant-based cannabinoid treatment products, committed to the discovery,